title: [The effects of surfactant-TA on bleomycin-induced lung injury and lung fibroblast proliferation].
abstract: We investigated whether artificial surfactant modified pulmonary fibrosis following the intratracheal administration of bleomycin (BLM 3.75 mg/kg) in rats. Twenty-four hours after the administration of bleomycin, the lungs were washed twice with surfactant-TA (S-TA, 1 mg/ml, 6 ml x 2 times), and replaced with 0.5 ml of 10 mg/ml S-TA. Fourteen days later the animals were sacrificed and the lungs were assayed for collagen content and pathologic changes. BLM-treated rats showed both increases in wet lung weights and lung collagen content, and a loss in body weights (due to lung injury and fibrosis), but these changes were significantly inhibited by the intratracheal administration of S-TA. In vitro studies demonstrated that S-TA inhibited lung fibroblast proliferation in a dose dependent manner (0.01-0.5 mg/ml). This inhibition was also seen in native rat lung surfactant and its protein and lipid components. However, S-TA, did not change the number of rat type II pneumocutes in culture, and likely protected type II cells from dedifferentiation. S-TA inhibited BLM-induced pulmonary fibrosis, probably by directly inhibiting lung fibroblast proliferation.
authors.affiliation: Department of Laboratory Medicine, Yamagata University School of Medicine.
authors.forename: M
authors.initials: M
authors.lastname: Ito
authors.forename: A
authors.initials: A
authors.lastname: Suwabe
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Tominaga
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D001688:Biological Products; D001761:Bleomycin / Q000009:adverse effects*; D002455:Cell Division / Q000187:drug effects; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D008168:Lung / Q000166:cytology*; D008297:Male; D011650:Pulmonary Alveoli / Q000166:cytology / Q000187:drug effects*; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000473:pathology*; D011663:Pulmonary Surfactants / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000903:Antibiotics, Antineoplastic; D001688:Biological Products; D011663:Pulmonary Surfactants; D001761:Bleomycin; C072197:beractant